Evidence map›Paper›PMID 36117294›Full record

ArticleCardiology journal2022

TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice.

Krzysztof J Filipiak, Miguel Camafort Babkowski, Matteo Cameli, Stefano Carugo, Claudio Ferri, Djamshid B Irisov, Krzysztof Narkiewicz, Ulugbek Nizamov, Leopoldo Pérez de Isla, Anna Tomaszuk-Kazberuk and 2 more

Open access · goldAbstract readConsensus Statement
In one paragraph

Article in Cardiology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 4 countries.

Krzysztof J FilipiakInstitute of Clinical Sciences, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland.
Miguel Camafort BabkowskiHypertension Unit, Hospital Clínic, University of Barcelona, Barcelona, Spain.
Matteo CameliDepartment of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy.
Stefano CarugoDepartment of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Cardiology Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan, Milan, Italy.
Claudio FerriUniversity of L'Aquila, MeSVA Department and San Salvatore Hospital, UOC Internal Medicine & Neohrology, Hypertension and Cardiovascular Prevention Unit, L'Aquila, Italy.
Djamshid B IrisovCardiac Arrhythmias Department, Republican Specialised Center of Cardiology, Tashkent, Uzbekistan.
Krzysztof NarkiewiczChair and Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland.
Ulugbek NizamovDepartment of Ischemic Heart Disease and Atherosclerosis, Republican Specialised Center of Cardiology, Tashkent, Uzbekistan.
Leopoldo Pérez de IslaDepartment of Cardiology, Hospital Clínico San Carlos, Madrid, Spain.
Anna Tomaszuk-KazberukDepartment of Cardiology, Medical University of Bialystok, Bialystok, Poland.
Andrea UngarGeriatric and Intensive Care Medicine, Hypertension Centre, University of Florence and Careggi Hospital, Florence, Italy.
Aleksandra Gąsecka1st Chair and Department of Cardiology, Medical University of Warsaw, Poland. gaseckaa@gmail.com.
Centre of Hydrometeorological Service · UZAzienda Ospedaliero-Universitaria Careggi · ITGdańsk Medical University · PLHospital Clínico San Carlos · ESMedical University of Białystok · PLMedical University of Warsaw · PLSan Salvatore Hospital · ITUniversitat de Barcelona · ESUniversity of Milan · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension and lipid disorders are two of the main cardiovascular risk factors. Both risk factors - if detected early enough - can be controlled and treated with modern, effective drugs, devoid of significant side effects, available in four countries as different as Italy, Spain, Poland, and Uzbekistan. The aim herein, was to develop this TIMES TO ACT consensus to raise the awareness of the available options of the modern and intensified dyslipidemia and arterial hypertension treatments. The subsequent paragraphs involves consensus and discussion of the deleterious effects of COVID-19 in the cardiovascular field, the high prevalence of hypertension and lipid disorders in our countries and the most important reasons for poor control of these two factors. Subsequently proposed, are currently the most efficient and safe therapeutic options in treating dyslipidemia and arterial hypertension, focusing on the benefits of single-pill combination (SPCs) in both conditions. An accelerated algorithm is proposed to start the treatment with a PCSK9 inhibitor, if the target low-density-lipoprotein values have not been reached. As most patients with hypertension and lipid disorders present with multiple comorbidities, discussed are the possibilities of using new SPCs, combining modern drugs from different therapeutic groups, which mode of action does not confirm the "class effect". We believe our consensus strongly advocates the need to search for patients with cardiovascular risk factors and intensify their lipid-lowering and antihypertensive treatment based on SPCs will improve the control of these two basic cardiovascular risk factors in Italy, Spain, Poland and Uzbekistan.

Indexed as

Cardiovascular DiseasesCOVID-19DyslipidemiasHypertensionAntihypertensive AgentsHumansLipidsLipoproteinsPolandProprotein Convertase 9Risk FactorsAntihypertensive AgentsLipidsLipoproteinsPCSK9 protein, humanProprotein Convertase 9cardiovascular preventionhypercholesterolemiahypertensionsingle-pill combination (SPC)

Identifiers

PMID36117294
PMCPMC9550320
OpenAlexW4296322306

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.